Researchers examined semaglutide use in U.S. adults with type 2 diabetes using the 2022 Medical Expenditure Panel Survey (n = 2,542) [1]. Our guide to GLP-1 insurance coverage explains why the covered product and the reason for prescribing matter. This analysis grouped people by income and insurance status.
What were the adjusted differences?
Adults with incomes above the median had higher odds of semaglutide use (OR 1.61, 95% CI 1.14–2.26). Private insurance was also associated with higher odds (OR 1.52, 95% CI 1.04–2.22) [1]. These are adjusted odds ratios. They do not give the absolute difference in the share of people taking semaglutide.
How does this relate to today’s prices?
The survey was cross-sectional and limited to adults with diagnosed type 2 diabetes. The guide to current GLP-1 price ranges explains how to interpret medication and program charges today. The 2022 survey did not measure how those current offers affect access.